No one has idea.This co has deal with USDA and they will generate huge tons of cash , just wait and see.
I bought 100K for long term.I will not be surprise if market cap goes to 100 M
Expect company to make 35Cents to 50 cents in next quarter.Revenue keep rising
just bought 2 X 110K
Propanc Health Group Corp (OTCMKTS:PPCH) is an exciting story developing in small caps that has skyrocketed out of sub penny land to become one of the top traded stocks on the bb’s. The stock is surpassing recent highs on another huge leg up.
The big move on PPCH comes on big news from the Company and heavy promotion from an Investment Newsletter called the Wealthy Biotech Trader as well as a paid feature in the NY Times Sunday Edition Magazine under Health Essentials: Cancer Prevention & Treatment on April 19th.
Propanc Health Group Corp (OTCMKTS:PPCH) is focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with their scientific and oncology consultants, they have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body.
Propanc’s lead drug candidate, PRP, is a once-daily pro-enzyme treatment as a clinically proven therapeutic option in the treatment and prevention of cancer. PRP would be the first therapy of its kind, as there are no FDA approved therapies used for the long-term prevention or management of these conditions. Propanc is focusing on providing oncologists and their patients with more effective metastatic cancer therapies with a substantially reduced side effect profile; specifically, colorectal and pancreatic cancers. Improvement is needed for the standard of care for late stage cancer, with the incumbent treatments causing significant adverse effects for the modest benefits provided.
Propanc is seeking potential licensing partners within the next 12-18 months and the Company is also investigating acquisition opportunities that will expedite their strategic growth and strengthen their portfolio. Company management has stated that once the development projects have sufficiently progressed down the development pathway and have commensurately achieved a major increase in value, they will seek a suitable licensing partner to complete the remaining development activities, obtain regulatory approval and market the product.
this is nothing, investors do not have any idea about the company and their product. undervalue stocks, In my opinion it is a pure steal if you have 1 M shares.
The syndrome belongs to a group of diseases called mucopolysaccharidoses (MPS). Specifically, it is known as MPS III.
•MPS I H (Hurler syndrome)
•MPS II, Hunter syndrome
•MPS IV (Morquio syndrome)
•MPS I S (Scheie syndrome)
hold on to your golden shares.